ViiV Healthcare Reports the EC’s Approval of Vocabria + Rekambys to Treat HIV
Shots:
- ViiV Healthcare (owned by GSK with Pfizer & Shionogi as shareholders) has received EC’s approval for Vocabria (cabotegravir) combined with J&J’s Rekambys (rilpivirine) to treat HIV-1 in virologically suppressed adolescents (≥12yrs. & ≥35kg), following CHMP opinion in Dec 2024
- MAA was based on 24wks. data from ongoing P-I/II (MOCHA) trial evaluating the safety, tolerability & PK profile of Vocabria + Rekambys long-acting injections among 144 adolescents
- Study showed virological suppression (plasma HIV-1 RNA value <50c/mL) in 96.5% (139/144) at wk.24. Additionally, 99% (139/141) preferred long-acting injections over daily oral meds
Ref: GSK | Image: ViiV Healthcare
Related News:- ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
